Blue Jet Healthcare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹22(6.36%)
Premium (ELP)
Blue Jet Healthcare Limited's achieved publicly listed status following its IPO debut on Nov 01, 2023 at the NSE, BSE platform. The offering successfully mobilized 2,42,85,160 Shares, with TBD allocated to corporate growth initiatives and ₹840.27 Cr providing liquidity to existing shareholders.
Investment participation occurred within the established price band of ₹329 to ₹346, starting from minimum lots of 43 shares. The subscription window from Oct 25, 2023 through Oct 27, 2023 enabled investor participation across market segments.
Share allocation was completed on Oct 30, 2023, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 1968, Blue Jet Healthcare is a science-led pharmaceutical company specializing in healthcare ingredients and intermediates. The company was the first in India to manufacture saccharin and its salts and has since expanded into contrast media intermediates for CT scans and MRIs. Its main product categories include contrast media intermediates, high-intensity sweeteners, and pharmaceutical intermediates and APIs. Blue Jet Healthcare offers process development, production capabilities, global regulatory support, and collaboration in advanced pharmaceutical development. The company operates three manufacturing facilities in Shahad, Ambernath, and Mahad, Maharashtra, with annual installed capacities of 200.60 KL, 607.30 KL, and 213.00 KL, respectively, as of June 30, 2023.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- One of the largest manufacturing capacities for contrast media intermediates in India.
- Operates in a niche segment with high entry barriers — limited competition and strong pricing power.
- Strong and long-term relationships, supported by long-duration contracts with leading multinational customers.
NA
- Akshay Bansarilal Arora
- Shiven Akshay Arora
- Archana & Akshay Arora
Blue Jet Healthcare Limited
Link Intime India Private Limited